Pfizer’s Chantix Move Seen as Positive Signal for Achieve Life Sciences
Analysts say Pfizer listing Chantix on TrumpRx may support Achieve Life Sciences and boost confidence in cytisinicline’s approval prospects.
/ 3 items
#ACHV↓
FDA Fast-Tracks First Vaping Cessation Treatment for Cytisinicline
Achieve Life Sciences receives FDA's National Priority Voucher for cytisinicline, potentially the first approved treatment to help people quit vaping and e-cigarettes.
FDA Reviews Achieve Life Sciences' Cytisinicline for Smoking Cessation
FDA accepted cytisinicline NDA for smoking cessation, with a PDUFA date of June 20, 2026. This marks a significant step, potentially offering the first new FDA-approved therapy in two decades to combat nicotine dependence, supported by strong clinical data and safety.